---
title: "Halozyme Therapeutics, Inc. (HALO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HALO.US.md"
symbol: "HALO.US"
name: "Halozyme Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T20:26:40.847Z"
locales:
  - [en](https://longbridge.com/en/quote/HALO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HALO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HALO.US.md)
---

# Halozyme Therapeutics, Inc. (HALO.US)

## Company Overview

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [alozyme.com](https://alozyme.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: B (0.37)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 39.12% |  |
| Net Profit YoY | -28.13% |  |
| P/B Ratio | 36.42 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7999260720.00 |  |
| Revenue | 1508458000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 99.40% | A |
| Profit Margin | 23.13% | A |
| Gross Margin | 72.18% | A |
| Revenue YoY | 39.12% | A |
| Net Profit YoY | -28.13% | D |
| Total Assets YoY | 21.68% | A |
| Net Assets YoY | -54.46% | E |
| Cash Flow Margin | 194.19% | B |
| OCF YoY | 39.12% | A |
| Turnover | 0.62 | B |
| Gearing Ratio | 91.78% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Halozyme Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "39.12%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-28.13%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "36.42",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7999260720.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1508458000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "99.40%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "23.13%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "72.18%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "39.12%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-28.13%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "21.68%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-54.46%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "194.19%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "39.12%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.62",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "91.78%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 22.93 | 40/386 | 23.64 | 14.44 | 13.65 |
| PB | 36.42 | 431/386 | 153.10 | 18.72 | 14.77 |
| PS (TTM) | 5.30 | 112/386 | 6.87 | 6.43 | 5.85 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 44% |
| Overweight | 2 | 22% |
| Hold | 2 | 22% |
| Sell | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 68.73 |
| Highest Target | 96.00 |
| Lowest Target | 57.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HALO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HALO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HALO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HALO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**